Core Viewpoint - Predictmedix AI Inc. successfully closed the first tranche of its non-brokered private placement, raising gross proceeds of $460,150 by issuing 9,203,000 units at a price of $0.05 per unit, indicating strong internal confidence in the company's future growth and innovation [1][2]. Financing Details - The private placement consisted of 9,203,000 units, each comprising one common share and one half of a common share purchase warrant, raising a total of $460,150 [2]. - Insiders subscribed $60,000 of the tranche, with Sheldon Kales and Dr. Rahul Kushwah each investing $30,000, reflecting confidence in the company's prospects [1][3]. - Each warrant allows the holder to purchase one half of a common share at a price of C$0.15 for 36 months, with potential acceleration of expiry if the share price meets certain conditions [2]. Regulatory Context - The insider participation in the private placement is classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from valuation and minority shareholder approval requirements [3]. Strategic Engagement - This financing round follows Predictmedix's active engagement with European capital markets, including participation in the 25th MK Investment Conference in Munich, aimed at expanding its shareholder base and building relationships with global investors [5]. - The company has also conducted a high-profile European road-show to engage influential family offices and institutional investors [5]. Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs or alcohol, fatigue, or mental illnesses [6].

Core Insights - WELL Health Technologies Corp. provides a corporate update on its subsidiary WELLSTAR Technologies, highlighting significant organic and inorganic growth, including a $62 million Series B financing round and strategic acquisitions [2][3][12]. WELLSTAR's Growth and Strategy - WELLSTAR has established itself as Canada's leading digital health platform, driven by organic growth and a growing recurring revenue base [3]. - The company aims for a potential public listing in 2026 while focusing on empowering clinicians with advanced digital tools [3]. OceanMD eReferral Platform - OceanMD has secured a significant eReferral contract, increasing WELLSTAR's Annual Recurring Revenue (ARR) by 16% [4][5]. - The platform now facilitates over 1.7 million eReferrals annually, supported by more than 20,000 physicians and 3,800 clinics across Canada [5][6]. - OceanMD has demonstrated improvements in patient care, including a 12% reduction in unnecessary MRIs and a 20% reduction in surgical wait times [7]. Recent Acquisitions - WELLSTAR has signed agreements to acquire two billing assets expected to generate approximately $4 million in annualized revenue with margins exceeding 20% [9]. - The acquisition of Mutuo Health Solutions enhances WELLSTAR's AI capabilities and aligns its products with clinical workflows [10]. Financial Performance - WELLSTAR reported Q3 revenue of $18.3 million, a 67% increase year-over-year, with organic growth of 26% [11]. - The company's ARR grew 63% year-over-year, indicating a scalable and durable business model [11]. Future Growth Plans - Following the $62 million financing, WELLSTAR is pursuing strategic acquisitions to expand its technology suite and aims for a $100 million annualized run rate [12]. - The company is actively advancing its M&A pipeline and has added a new member to its corporate development team [12].

Core Points - Henry Schein, Inc. will present at Piper Sandler's Healthcare Conference on December 2, 2025, at 9:00 a.m. Eastern time [1] - The company is the largest provider of health care solutions to office-based dental and medical practitioners [1][4] - Henry Schein's sales reached $12.7 billion in 2024, with a compound annual growth rate of approximately 11.2% since becoming public in 1995 [4] Company Overview - Henry Schein operates a centralized and automated distribution network, offering over 300,000 branded and corporate brand products [3] - The company employs more than 25,000 Team Schein Members globally, serving over 1 million customers with more than 300 solutions [2] - Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories [4]

Core Insights - Enterprises in Germany are increasingly integrating AI into application development, focusing on innovation, compliance, and precision engineering [1][2][3] Group 1: AI Integration and Compliance - Companies in Germany are prioritizing the ethical use of AI, which is essential for service delivery, and are seeking providers that can ensure compliance with regulatory requirements, including data protection [2][3] - The 2025 ISG Provider Lens report indicates that GenAI implementations have progressed from exploration to execution, significantly changing how enterprises approach application development and management [2][4] Group 2: Industry Trends and Government Initiatives - The report highlights that mobile application development and public sector digitalization are key trends, with the government expanding e-government platforms and emphasizing usability, security, and data localization [4][5] - In healthcare, the demand for regulated application development is rising, driven by legislation that allows doctors to prescribe digital health apps, necessitating compliance with performance and privacy standards [5][6] Group 3: Market Dynamics and Provider Evaluation - The report evaluates 26 providers in the AI-driven application development services sector, naming adesso SE, Allgeier, and others as leaders, while Coforge is recognized as a Rising Star [8] - LTIMindtree is acknowledged as the global ISG CX Star Performer for 2025, achieving the highest customer satisfaction scores among AI-driven ADM service providers [9]

Nov 12, 2025 4:16 PM Eastern Standard Time HealthWarehouse.com Reports Results for Third Quarter 2025 Share Reports 7% decline in sales due to slowing DTC sales and shifts in GLP-1 market CINCINNATI--(BUSINESS WIRE)--HealthWarehouse.com, Inc. (OTCQB:HEWA) announced today that its net sales for the third quarter ended September 30, 2025, totaled $8.4 million, a 7% decrease from the quarter ended September 30, 2024. The Company reported a net loss of $72,000 and Adjusted EBITDA of $343,000 for the quarter. Ye ...

Core Insights - Claritev Corporation reported Q3 2025 revenues of $246.0 million, a 6.7% increase from Q3 2024, with a net loss of $69.8 million and an adjusted EBITDA of $155.1 million, reflecting a 9.5% increase compared to the previous year [1][6] - The company has raised its full-year 2025 revenue and adjusted EBITDA guidance, indicating confidence in its strategic plan and growth trajectory [1][5] Financial Performance - Q3 2025 revenues reached $246.0 million, up from $230.5 million in Q3 2024, marking a 6.7% growth [6] - The net loss for Q3 2025 was $69.8 million, significantly improved from a net loss of $391.5 million in Q3 2024 [6] - Adjusted EBITDA for Q3 2025 was $155.1 million, an increase of 9.5% from $141.6 million in Q3 2024, with an adjusted EBITDA margin of 63.1% compared to 61.5% in the prior year [1][6] - The company processed approximately $45.9 billion in claim charges during Q3 2025, identifying potential medical cost savings of around $6.1 billion [6] Strategic Direction - The CEO emphasized that 2025 is the "Year of the Turn" for Claritev, highlighting the company's focus on executing its strategic plan, "The Way Up," to drive growth in core solutions and expand market segments [2][3] - The company has renewed contracts with its top ten clients and is experiencing growth in its international business, which presents further opportunities [3] Updated Guidance - Claritev updated its full-year 2025 guidance, projecting revenue growth of 3.2% from FY 2024, up from a previous estimate of flat to 2% [5] - The adjusted EBITDA margin guidance remains between 62.5% to 63.0% [5] Cash Flow and Liquidity - The company reported net cash provided by operating activities of $19.9 million for Q3 2025, down from $72.8 million in Q3 2024 [6] - Free cash flow for Q3 2025 was $(16.3) million, compared to $41.1 million in Q3 2024 [6] - As of the end of Q3 2025, Claritev had $39.2 million in unrestricted cash and cash equivalents [6]

Core Insights - Hinge Health, Inc. (NYSE:HNGE) experienced a significant decline in stock price, dropping 15.06% to $45.39 due to disappointing earnings results, marking the end of a three-day winning streak [1][3] Financial Performance - The company reported a net loss attributable to shareholders of $1.8 million for the third quarter, a decline from a net income of $72,000 in the same period last year, primarily due to increased operating expenses and operational losses [2][3] - Operating loss increased to $6.1 million, representing a 56.4% rise from the $3.9 million loss in the comparable period [3] - Revenues surged by 53% to $154.2 million, up from $100.6 million year-on-year [3] Future Outlook - Hinge Health remains optimistic about its future, projecting revenues for 2025 to reach between $572 million and $574 million, indicating a 47% year-on-year growth at the midpoint [3] - For the fourth quarter, the company anticipates revenue growth of 33% year-on-year, estimating revenues in the range of $155 million to $157 million [4]

Core Insights - Aceso Interactive has formed a strategic partnership with Samsung Electronics America to enhance patient engagement and digital signage solutions in healthcare settings across North America [1][3]. Company Overview - Aceso Interactive specializes in patient engagement and healthcare communication technology, providing scalable solutions for hospitals [4]. - Samsung Electronics America is recognized for its innovative digital display technology, aimed at improving communication and operational efficiency in healthcare [5]. Partnership Details - The collaboration integrates Aceso's enterprise-grade software with Samsung's display technology, specifically utilizing Samsung's TIZEN and TEP operating systems [2][3]. - Aceso's software has been deployed in a seven-hospital health system in the Northeast US, utilizing over 1,000 Samsung displays, demonstrating the scalability and flexibility of the combined solutions [2][3]. Benefits of the Collaboration - The partnership aims to transform the healthcare experience by enhancing communication, patient engagement, and operational efficiency within a unified ecosystem [3]. - The integrated solution supports various functions, including patient education, virtual care, entertainment, staff messaging, and facility-wide communications, thereby improving the overall patient experience [3][4].

Core Insights - Bevel is a New York-based startup that aims to fill the gap in understanding the connections between various health data points collected from wearable devices and daily habits [1][2] - The company has raised $10 million in Series A funding from General Catalyst to scale its AI health companion platform [1][2] User Growth and Engagement - Bevel's user base has grown over eight times in the past year, surpassing 100,000 daily active users, making it one of the fastest-growing health apps in the U.S. [2] - Users engage with the app an average of eight times a day, with a 90-day retention rate exceeding 80%, which is notable in an industry where users often drop off after achieving short-term fitness goals [2] Unique Value Proposition - Unlike traditional health apps that focus on single areas like steps, sleep, or nutrition, Bevel integrates these functionalities into one platform [3] - The app is accessible for a broader audience, with a subscription model of $6 per month or $50 per year, avoiding the high costs associated with hardware devices [3][6] Technology Integration - Bevel integrates with popular wearable devices such as Apple Watch and continuous glucose monitors like Dexcom and Libre, with plans to expand compatibility with other devices like Garmin [3][5] Founders' Background - The founders, Grey Nguyen and Ben Yang, have personal experiences with health challenges that inspired the creation of Bevel, emphasizing the importance of tracking and understanding health data [6][7] - The company aims to help users make small, cumulative changes to their health habits over time, rather than treating health as a series of tasks [2][7] Future Plans - Following the recent funding, Bevel plans to expand its team and develop more health services and partnerships, rather than creating its own wearable devices [7]

Core Insights - The health-technology company experienced sales growth and improved productivity measures, which positively impacted earnings in the third quarter [1] Group 1: Sales Growth - The company reported significant sales growth in the third quarter, contributing to overall financial performance [1] Group 2: Productivity Measures - Enhanced productivity measures were implemented, leading to increased efficiency and profitability [1] Group 3: Earnings Impact - The combination of sales growth and productivity improvements resulted in a notable uplift in earnings for the quarter [1]